The FDA's cautionary word on statin use has stirred up a back-and-forth risk-benefits debate. When the agency announced last week that it would highlight the risk of Type 2 diabetes on the cholesterol drugs' labels, some prominent heart doctors issued their own warnings: Don't worry too much about that risk. For most patients, the heart benefits of statins outweigh the "small" risk of developing diabetes.
Big-selling cholesterol drugs got new warnings on their labels, but the cautionary language about blood sugar and memory loss isn't expected to diminish their popularity much.
Lipitor just got shot down by a healthcare plan. As The Wall Street Journal reports, WellPoint ($WLP) is planning to stop covering Pfizer's ($PFE) brand-name cholesterol drug April 1, favoring its
The DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 2007...
Pfizer ($PFE) and Eli Lilly ($LLY) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earnings
Pfizer ($PFE) faces another stumbling block on its Lipitor obstacle course. As The Wall Street Journal reports, Express Scripts ($ESRX) is moving the cholesterol drug to a less-favorable spot on its
No question, the cholesterol-fighting statin drugs have been a powerhouse class for Big Pharma. One of them--Pfizer's ($PFE) Lipitor--was the best-selling branded medication of all time, and plenty
The latest figures on Lipitor sales suggest that Pfizer's ($PFE) aggressive sales strategies might—just might—be working. As The Associated Press reports, new IMS Health numbers show
Pfizer is thinking small these days. In keeping with the deal-making theme at the J.P. Morgan conference, Pfizer ($PFE) CEO Ian Read carefully mapped out the pharma giant's near-term strategy, with
Biotech startup Warp Drive Bio has scored $125 million in financing from a syndicate that features the French drug giant Sanofi ($SNY) along with founding backer Third Rock Ventures and the VC firm